Insmed Incorporated (INSM) fair value analysis
Nasdaq · Updated 2026-09-07
Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for serious and rare diseases, with a focus on respiratory and rare infectious diseases. The company operates in the United States and internationally, serving patients across multiple markets.
Valuation status
Awaiting full valuationINSM does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $98.45
- Sector
- Healthcare
- 12-month range
- $98.45–$211.41
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Moderate
- RSI zone
- Neutral
- 50/200-day trend
- Downtrend
- 52-week position
- The bottom quarter of its range
What our data shows for INSM
- Shares are trading in the lower third of their 12-month price range of $98.45–$211.41.
- The 14-day relative strength index sits at a neutral 67.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for INSM
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent INSM news
TickrTrends' derived news-sentiment signal for INSM is currently leaning positive, computed from recent coverage.
- INSM Looks 38.8% Undervalued on GF Value™ Despite Profitability Challenges (gurufocus.com, 2026-09-03)
TickrTrends take: Insmed Incorporated trades in a valuation environment where analytical models suggest potential undervaluation relative to intrinsic value estimates, though TickrTrends maintains an awaiting full valuation status pending more complete data assessment. The Healthcare sector positioning combined with reported profitability challenges creates a mixed picture that valuation-focused investors should monitor for clarity on earnings trajectory and cash flow sustainability. Observers of INSM should track whether operational improvements materialize to support the valuation gap suggested by quantitative models. - Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges? (finance.yahoo.com, 2026-09-02)
TickrTrends take: Insmed operates in the Healthcare sector where valuation assessments depend heavily on long-term pipeline prospects relative to near-term financial performance. The company currently awaits full valuation analysis from TickrTrends, meaning comprehensive metrics across growth, profitability, and cash flow have not yet been fully quantified. Investors focused on valuation should monitor whether management can demonstrate a clear path from current challenges to sustainable revenue growth, as this distinction will be critical to establishing an appropriate fair value range.
What people are saying
Follow the INSM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is INSM stock undervalued?
INSM does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is INSM's TickrTrends verdict?
INSM is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is INSM overbought or oversold?
INSM's 14-day RSI is in neutral territory - neither overbought nor oversold.